Q. With lifestyle diseases emerging as a major public health challenge, examine how new-generation therapies and medical technologies can improve...

Q. With lifestyle diseases emerging as a major public health challenge, examine how new-generation therapies and medical technologies can improve disease management and health outcomes in India. (15 marks 250 Words)

Question

Q. With lifestyle diseases emerging as a major public health challenge, examine how new-generation therapies and medical technologies can improve disease management and health outcomes in India. (15 marks 250 Words)

Model Answer

Q. With lifestyle diseases emerging as a major public health challenge, examine how new-generation therapies and medical technologies can improve disease management and health outcomes in India. (15 marks 250 Words)

Paper

GS III

Subject

Science & Technology

Syllabus as Per Notification

Science and Technology - Developments and their applications and effects in everyday life.

Topic

New generation therapies and Medical technologies

Approach:

Introduction

Introduce with the NCDs burden as a major public health challenge in India

Body

Briefly explain what are the New-generation therapies and medical technologies with relevant examples.

Role of New-Generation Therapies and Medical Technologies

Improving Treatment Adherence and Long-term Disease Management, Enabling Precision and Personalised Medicine, Targeted Drug Delivery through Nanomedicine, Facilitating Early Diagnosis and Continuous Monitoring, Promoting Preventive and Predictive Healthcare and Improving Health Outcomes and Quality of Life.

Challenges in Harnessing New-Generation Therapies for Lifestyle Diseases

Unequal Access to Advanced Therapies, Regulatory & Quality Control Concerns, Medicalisation of Lifestyle Disorders and Limited Health-System Preparedness.

Way forward

Establishing Robust Regulatory Framework for Emerging Therapies, Promoting Quality and Affordable Innovation, Integrating Pharmacotherapy with Lifestyle and Preventive Healthcare and Building a Digital and Inclusive Health-System Ecosystem.

Conclusion

Conclude by emphasising the need for changing from reactive treatment to predictive, preventive and personalised medicine (PPPM) framework, there by realising Universal Health coverage and SDG-3.

Context

Novo Nordisk launched its weekly insulin shot (Awiqli) in India (World's first once-weekly insulin)

Introduction

With Non-Communicable Diseases (NCDs) accounting for nearly two-thirds of total deaths, lifestyle diseases have emerged as major public health challenge in India. According to the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), around 4.68 crore individuals have been diagnosed with diabetes and nearly 7 crore with hypertension. In this context, new-generation therapies and medical technologies offer wider opportunities for improving disease management and health outcomes.

Body

New-generation therapies and medical technologies

New-generation therapies and medical technologies refer to advanced healthcare interventions that leverage innovations in biotechnology, genomics, nanotechnology and artificial intelligence to enable more precise, personalised and preventive care. Some of the key components include;

Precision Medicine: Genomics, biomarkers, personalised therapies.

Advanced Therapeutics: Weekly insulin (Awiqli), GLP-1 drugs, CAR-T therapy, gene editing, nanomedicine.

Digital Health Technologies: Artificial Intelligence, wearables, telemedicine, digital health records.

Advanced Diagnostics & Monitoring: Continuous Glucose Monitoring Systems (CGMS), predictive analytics and early screening tools.

Role of New-Generation Therapies and Medical Technologies in improving disease management and health Outcomes

Improving Treatment Adherence and Long-term Disease Management

A major challenge in lifestyle diseases is poor adherence to lifelong treatment regimens. The introduction of Awiqli (Insulin Icodec), the world's first once-weekly insulin, reduces injections from 365 to merely 52 annually, addressing treatment fatigue and fear of injections.

Enabling Precision and Personalised Medicine

Advances in genomics, biomarkers and AI are enabling therapies tailored to individual genetic and metabolic profiles rather than a one-size-fits-all approach.

Recent advances in molecular therapies (CAR-T Cell therapy) and gene-editing technologies (CRISPR) are paving the way for highly targeted interventions.

Targeted Drug Delivery through Nanomedicine

Recent Department of S&T (DST) supported research has developed a next-generation biodegradable nanocarrier that delivers siRNA to silence key cancer-driving genes (MCL-1 and Survivin).

The technology holds promise for future treatment of metabolic and inflammatory disorders associated with lifestyle diseases.

Facilitating Early Diagnosis and Continuous Monitoring

Wearables such (Whoop, Apple watches, Smart watches), Continuous Glucose Monitoring Systems (CGMS) and AI-assisted diagnostics provide real-time health monitoring, thereby preventing severe complications and hospitalisations.

Promoting Preventive and Predictive Healthcare

Artificial Intelligence and digital health platforms enable risk prediction, personalised lifestyle interventions and population-level disease surveillance.

Integration with initiatives such as the Ayushman Bharat Digital Mission (ABDM) and digital health records can ensure continuity of care and support preventive healthcare.

Improving Health Outcomes and Quality of Life

Early diagnosis, personalised interventions and targeted therapies can reduce premature mortality, disability and complications associated with NCDs.

These technologies can improve quality of life, enhance healthy life expectancy and contribute towards achieving SDG Target 3.4 of reducing premature mortality from NCDs.

Challenges in Harnessing New-Generation Therapies for Lifestyle Diseases

Unequal Access to Advanced Therapies

Despite technological breakthroughs, therapies such as weekly insulin, GLP-1 drugs and nanomedicine remain expensive and largely concentrated in urban tertiary-care centres.

Regulatory, Quality Control Concerns

The rapid expansion of novel therapies poses challenges relating to bioequivalence standards, quality assurance, pharmacovigilance and regulation of digital health technologies.

Example: Quality concerns regarding multiple Semaglutide generics.

Medicalisation of Lifestyle Disorders

Overreliance on pharmacological interventions without addressing dietary habits, physical activity and preventive healthcare can lead to unsustainable outcomes and adverse effects.

Limited Health-System Preparedness

Successful deployment of New Generation therapies requires strong digital infrastructure, interoperable health records, specialist manpower and advanced diagnostic capabilities.

Way forward:

Establishing Robust Regulatory Framework for Emerging Therapies

Strengthening Central Drugs Standard Control Organization (CDSCO), prescription protocols, pharmacovigilance mechanisms for safe deployment of emerging therapies.

Best Practice: US FDA's Sentinel Initiative continuously monitors post-market safety of drugs and medical devices using real-world data.

Promoting Quality and Affordable Innovation

India must leverage its pharmaceutical capabilities to ensure affordable access by encouraging indigenous R&D under initiatives such as BioE3 Policy and PLI schemes.

Integrating Pharmacotherapy with Lifestyle and Preventive Healthcare

Ensuring new-generation therapies complementing lifestyle modifications by integrating medication with nutrition, physical activity and behavioural counselling.

Best Practice: Finland's North Karelia Project significantly reduced cardiovascular mortality through combination of community-level dietary changes and Physical activity interventions.

Building a Digital and Inclusive Health-System Ecosystem

Strengthening the Ayushman Bharat Digital Mission (ABDM), interoperable electronic health records and digital health infrastructure to enable predictive and personalised healthcare.

Best Practice: Estonia's e-Health System shows that how interoperable digital health records can improve continuity of care and healthcare efficiency.

Conclusion

As India moves towards becoming a developed nation by 2047, the convergence of biotechnology, artificial intelligence and digital health can fundamentally redefine healthcare delivery, from reactive treatment to predictive, preventive and personalised medicine (PPPM). If supported by ethical regulation, affordable innovation and inclusive access, new-generation therapies not only improve health outcomes but also transform India's demographic dividend into a healthy and productive human capital base, thereby advancing the vision of Universal Health Coverage and SDG-3.